How much funding has Culmination Bio raised?

Culmination Bio has raised $10.0M in total funding, most recently a Seed round.

Who are Culmination Bio's investors?

Culmination Bio's investors include Amgen, Merck Global Health Innovation Fund.

When was Culmination Bio founded?

Culmination Bio was founded in 2022.

Where is Culmination Bio headquartered?

Culmination Bio is headquartered in Utah, United States.

What industry is Culmination Bio in?

Culmination Bio operates in Biotech, Healthcare.

How many employees does Culmination Bio have?

Culmination Bio has 11-50 employees.

Culmination Bio

United States · Founded 2022 · $10.0M raised

Biotech

Healthcare

Headquarters: Utah
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: culmination.com
Total Funding: $10.0M
Last Round: $10.0M SeedNov 2023
Rounds: 1

About

Culmination Bio is a biotech company spun out of Intermountain Health that builds an anonymized, de-identified patient-data intelligence platform combining omics-level and real-world clinical data to generate novel diagnostic and therapeutic insights. Led by CEO Lincoln Nadauld, the company launched publicly in March 2023 with backing from Intermountain Ventures and has since formed data and research partnerships with Merck, Amgen, and BillionToOne to advance precision medicine and oncology diagnostics.

Summary

Culmination Bio is a Biotech company based in United States, founded in 2022. It has raised $10.0M in total across 1 round, most recently a $10.0M Seed round in Nov 2023. Investors include Amgen and Merck Global Health Innovation Fund.